Carnitne Palmitoyltransferase II Defciency, a Rare Cause of Rhabdomyolysis: A Case Report
Introduction: Muscle weakness and rhabdomyolysis have a wide range of differential diagnosis. In many situations, they are induced by seizure, trauma, drugs, and toxins. They could also be due to inflammatory or metabolic myopathies. Identifying the exact cause is crucial and sometimes challenging.
Case Presentation: A 23-year-old man was admitted to our hospital with muscle weakness, fatigue, dyspnea, and dark urine, all preceded by flu-like symptoms, myalgia, and fever. Due to reduced muscle strength, dark urine, elevated serum creatine kinase, and serum creatinine, he was diagnosed with rhabdomyolysis and acute kidney injury. Muscle biopsy was performed three years before for the patient, due to a history of similar episodes and exercise intolerance. Because of recurrent episodes of muscle weakness and rhabdomyolysis along with the negative muscle biopsy for inflammatory myopathies, we suspected metabolic myopathy as a cause. Therefore, metabolic screening was performed for the patient, and he was diagnosed with metabolic myopathy known as Carnitine Palmitoyltransferase II (CPT II) deficiency.
Conclusion: In patients with recurrent rhabdomyolysis, we should consider inherited myopathies, especially carnitine palmitoyltransferase II deficiency and glycogen storage disease type V (McArdle disease) as likely causes. CPT II deficiency is regarded as a preventable cause of recurrent rhabdomyolysis. Therefore, by early diagnosis of this disorder we could prevent recurrent episodes of rhabdomyolysis and ultimately avoid life threatening complications like acute kidney injury.
 Selva-O’Callaghan A, Trallero-Araguás E, Martnez MA, Labrador-Horrillo M, Pinal-Fernández I, Grau-Junyent JM, et al. Inﬂammatory myopathy: Diagnosis and clinical course, specifc clinical scenarios and new complementary tools. Expert Review of Clinical Immunology. 2015; 11(6):737- 47. [DOI:10.1586/1744666X.2015.1035258] [PMID]
 van Adel BA, Tarnopolsky MA. Metabolic myopathies: Update 2009. Journal of Clinical Neuromuscular Disease. 2009; 10(3):97- 121. [DOI:10.1097/CND.0b013e3181903126] [PMID]
 Tarnopolsky MA. Metabolic Myopathies. Contnuum (Minneap Minn). 2016; 22(6):1829-51. [DOI:10.1212/CON.0000000000000403] [PMID]
 Scalco RS, Gardiner AR, Pitceathly RD, Zanoteli E, Becker J, Holton JL, et al. Rhabdomyolysis: A genetc perspectve. Orphanet Journal of Rare Diseases. 2015; 10:51. [DOI:10.1186/s13023-015-0264-3] [PMID] [PMCID]
 Koo P, Sethi JM. Metabolic myopathies and the respiratory system. Clinics in Chest Medicine. 2018; 39(2):401-10. [DOI:10.1016/j. ccm.2018.02.001] [PMID]
 Alečković-Halilović M, Mešić E, Sinanović O, Zukić S, Mustedanagić J. Carnitne palmitoyl transferase defciency-unrecognized cause of recurrent acute kidney injury. Renal Failure. 2013; 35(5):732-4. [DO I:10.3109/0886022X.2013.780979] [PMID]
 Topçu Y, Bayram E, Karaoğlu P, Yiş U, Bayram M, Kurul SH. Carnitne palmitoyl transferase II defciency in an adolescent presentng with rhabdomyolysis and acute renal failure. Pediatric Emergency Care. 2014; 30(5):343-4. [DOI:10.1097/PEC.0000000000000127] [PMID]
 Joussain C, Lamireau D, Espil-Taris C, De Précigout V, Vianey-Saban C, Llanas B, et al. A 10-year-old boy with dark urine and acute kidney injury. Pediatrics and Neonatology. 2011; 26(8):1229-33. [DOI:10.1007/s00467-011-1763-7] [PMID]
 Zhang LX, Gao PM. [A case report of carnitne palmitoyltransferase II defciency (Chinese)]. Zhongguo Dang Dai Er Ke Za Zhi. 2009; 11(2):1p. [PMID]  Zhao X, Li A, Soni M, Muriello MJ, Jones CH, Whiter WL. McArdle disease: A “pediatric” disorder presentng in an adult with acute kidney injury. CEN Case Reports. 2017; 6(2):156-60. [DOI:10.1007/
s13730-017-0265-2] [PMID] [PMCID]
 Delaney NF, Sharma R, Tadvalkar L, Clish CB, Haller RG, Mootha VK. Metabolic profles of exercise in patents with McArdle disease or mitochondrial myopathy. Proceedings of the Natonal Academy of Sciences. 2017; 114(31):8402-7. [DOI:10.1073/pnas.1703338114] [PMID] [PMCID]
 Balasubramanian M, Jenkins TM, Kirk RJ, Nesbit IM, Olpin SE, Hill M, et al. Recurrent rhabdomyolysis caused by carnitne palmitoyltransferase II defciency, common but under-recognised: Lessons to be learnt. Molecular Genetcs and Metabolism Reports. 2018; 15:69-70. [DOI:10.1016/j.ymgmr.2018.02.008] [PMID] [PMCID]
 Fontaine M, Kim I, Dessein AF, Menton-Mulliez K, Dobbelaere D, Douillard C, et al. Fluxomic assay-assisted diagnosis orientaton in a cohort of 11 patents with myopathic form of CPT2 defciency. Molecular Genetcs and Metabolism. 2018; 123(4):441-8. [DOI:10.1016/j.ymgme.2018.02.005] [PMID]
 Deutsch M, Vassilopoulos D, Sevastos N, Papadimitriou A, Vasiliou K, Archimandrits AJ. Severe rhabdomyolysis with hypoglycemia in an adult patent with carnitne palmitoyltransferase II defciency. European Journal of Internal Medicine. 2008; 19(4):289-91. [DOI:10.1016/j.ejim.2007.04.025] [PMID]
 Gjorgjievski N, Dzekova-Vidimliski P, Petronijevic Z, Selim G, Dejanov P, Tozija L, et al. Carnitne palmitoyltransferase II defciency (CPT II) followed by rhabdomyolysis and acute kidney injury. Open Access Macedonian Journal of Medical Sciences. 2018; 12(6):666-8. [DOI:10.3889/oamjms.2018.158] [PMID] [PMCID]